INS and diabetes mellitus: Biosimilars available in the Belgian ambulatory care include TNF-alpha inhibitors for the treatment of immune mediated inflammatory diseases (i.e., adalimumab, etanercept) and insulins for the treatment of diabetes mellitus (i.e., insulin glargine).